[Featured Stock] NKMAX Gains on Approval of Canadian Alzheimer's Phase 1/2a Clinical Trial Plan

NKMax is on the rise following news that it will conduct Alzheimer's clinical trials in Canada after the United States.

As of 10:07 AM on the 28th, NKMax was trading at 6,270 KRW, up 340 KRW (5.73%) from the previous trading day.

NKMax's subsidiary, NKGen Biotech (NASDAQ: NKGN), announced on the 27th (U.S. local time) that it received approval for a clinical trial application (CTA) from Health Canada for a Phase 1/2a Alzheimer's study.

This Canadian clinical trial will be conducted on patients with moderate Alzheimer's disease, similar to the U.S. trial. In Phase 1, the dosage of the autologous NK cell therapy ‘SNK01’ will be determined, and in Phase 2, safety and efficacy will be evaluated in moderate patients.

On the day the news was announced, NKGen Biotech closed up 17.7% on the Nasdaq market, reaching an intraday high of 30.1%.

NKGen Biotech is also conducting a Phase 1/2a Alzheimer's clinical trial in the U.S., which recently began enrolling its first patients this month.

A company representative stated, “Since it is estimated that more than 350 people develop dementia daily in Canada, patient recruitment will be easy, and the related market is expected to continue expanding. Now that we can conduct clinical trials targeting moderate patients in Canada following the U.S., we will be able to demonstrate the potential of SNK.”

Meanwhile, NKGen Biotech announced that the final results of the Phase 1 clinical trial in Mexico demonstrated both safety and efficacy in a total of 10 Alzheimer's patients (5 mild, 5 moderate to severe). Notably, unlike existing treatments, the disease progression was halted and improvement was confirmed.

This content was produced with the assistance of AI translation services.